Lattanzi, S C <br/><br/>
Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up.  [electronic resource] 

 -  Melanoma research  Oct 1995 
 - 365-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0960-8931 
<br/><br/><label>Standard No.: </label>10.1097/00008390-199510000-00010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Carmustine--administration & dosage<br/>Cisplatin--administration & dosage<br/>Dacarbazine--administration & dosage<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Sex Characteristics<br/>Survival Rate<br/>Tamoxifen--administration & dosage